Given this evidence, the present trial aimed to assess whether marine ω-3 PUFA supplementation enhances FFAR4 activation in PBMCs and thereby contributes to the reduction in inflammatory markers in individuals with obesity. Here, FFAR4 is linked to obesity due to melanocortin 4 receptor deficiency.